Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1a) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF)

Acta Oncologica

Volumn 30, Issue 8, 1991, Pages 923-931

  Mellstedt, H ^a,b   Frudin J E ^a,b   Ragnhammar, P ^a,b   Masucci, G ^a,b   Ljungberg, A ^a,b   Hjelm, A L ^a,b   Fagerberg, J ^a,b   Lindemalm, C ^a,b   Osterborg A ^a,b   Wersall P ^a,b   Christensson, B ^a,b   Shetye, J ^a,b   Biberfeld, P ^a,b   Makower, J ^a,b   Cedermark, B ^a,b   Erwald, R ^a,b   Nathansson, J ^a,b   Magnusson, I ^a,b   Rrieger, A ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

Colorectal carcinoma; GM CSF; Humans; Monoclonal antibodies; Therapy

Indexed keywords

COMPLEMENT; EDRECOLOMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ALLERGIC REACTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; CELL INFILTRATION; COLORECTAL CARCINOMA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFERENCE PAPER; CONSTIPATION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DOSE RESPONSE; DRUG RESPONSE; EFFECTOR CELL; FEVER; HUMAN; IMMUNE COMPLEX DISEASE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; MONOCYTE; MONONUCLEAR CELL; NAUSEA; PRIORITY JOURNAL; SHIVERING; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMAN; IMMUNOGLOBULIN G; REMISSION INDUCTION; SUPPORT, NON-U.S. GOV'T;

EID: 0026341175     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869109088245     Document Type: Article

References (25)

1. Monoclonal antibodies and human tumors; pathological and clinical aspects
2. Efficient selection of human tumor growth-inhibiting monoclonal antibodies
3. A monoclonal antibody defined antigen associated with gastro-intestinal cancer is a ganglioside containing sia-lylated lacto-N-fucopen-taose II
4. Isolation and characterization of a carcinoma-associated antigen
5. Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody: Isolation and characterization by mass spectrometry and NMR spectro-scopy
6. Monoclonal antibodies specific immunotherapy of gastro-intestinal tumors
7. The clinical use of monoclonal antibodies. MAb 17-IA, in the treatment of patients with metastatic colorectal carcinoma
8. Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma
9. Clinical trial of Wistar Institute 17–1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma
10. Initial trial use of murine monoclonal antibodies as immunotherdpeutic agents for gastrointestinal adenocarcinoma
11. Trial of therapy with monoclonal antibody 17-IA in pancreatic carcinoma: preliminary results
12. Monoclonal antibodies in cancer therapy
13. The natural history of primary and secondary malignant tumors of the liver. 1. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy
14. Prognostic factors influencing survival of patients with advanced colo-rectal cancer: Hepatic-artery infusion versus systemic intravenous chemotherapy for liver metastases
15. Granulocyte-monocyte-colony-stimulating factor augments the cyto-toxic capacity of lymphocytes and monocytes in antibody dependent cellular cytotoxicity
16. Immunohistochemical monotoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb17-1A)
17. Isolation and characterization of autologous blood mononuclear cells used for auto-infusion together with monoclonal antibodies in tumor treatment
18. Pharmacokinetics of the mouse monoclonal antibody 17-IA in cancer patients receiving various treatment schedules
19. Localization of an antitumour monoclonal antibody in human tumour xenografts: Kinetic and quantitative studies with the 791T/36 antibody
20. 2A monoclonal antibodies correlates with antibody density on tumor cells
21. Clinical effects of monoclonal antibodies (MAbl7–1A) in patients with metastatic colorectal carcinomas
22. Monoclonal antibodies against gastrointestinal tumor-associated antigens isolated as monosialogangliosides
23. Monoclonal antibody therapy of lymphoid malignancy
24. Tumors undergoing rejection induced by monoclonal antibodies of the IgG, isotope contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis
25. 2)